Sequence of Returns Risk: What 2024–2025 Retirees Must Know
Retired into the bull market peak? Sequence of returns risk is no longer hypothetical. Here's what the math actually looks like — and what to do about it.
← All Topics
Investing
Investing
Bull and bear cases, fundamental analysis, and market context for self-directed investors who want rigorous research — not recommendations.
Private Credit for Retail Investors: What the $1.7 Trillion Market Actually Looks Like Up Close
Private credit is now accessible to retail investors through ETFs, BDCs, and interval funds — each with different liquidity terms and structural risks. See the full breakdown.
Is Gold a Hedge or a Bubble in 2026? What the Correction Revealed
Gold hit $5,589 then crashed 27% in seven weeks — while geopolitical risk stayed high. Here's what the stress test reveals about gold investment in 2026.
The ABUSA Trade and Your 401(k): What to Check Before You Rebalance
The ABUSA trade is reshaping 401k international investing. Most retirement savers are already below the diversification floor. Here's the data — and what to audit.
The $13 War Premium Inside Your Energy ETF: What Goldman's Math Says About XLE and XOP Now
Goldman puts $13/barrel on the energy ETF war premium from Iran. Here's what history says happens when it unwinds — and which ETF carries the most risk.
SpaceX IPO: How the 5% Float and Lock-Up Waiver Shape Retail Risk
SpaceX IPO 2026 offers retail investors 3x the usual allocation. Before you read that as an advantage, look at what the deal structure actually does to you.
Cabaletta Bio (CABA) Stock Analysis: Five Make-or-Break Catalysts in 2026
Cabaletta Bio (CABA) trades at $3 against a $14.50 analyst target. Here are the five catalysts in the next 12 months that will resolve that gap — or close the company.